New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Sight Sciences, Inc.

Contributing Author

Recent Articles by Sight Sciences, Inc.

Jan-13	Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights SGHT GlobeNewswire
Nov-11	New Peer-Reviewed Publications Highlight Effectiveness of OMNI Surgical System with TruSync Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans SGHT GlobeNewswire
Nov-06	Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance SGHT GlobeNewswire
Nov-06	Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer SGHT GlobeNewswire
Nov-04	Sight Sciences to Present at Two Upcoming Investor Conferences SGHT GlobeNewswire
Oct-23	Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025 SGHT GlobeNewswire
Oct-17	Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare Interventional Dry Eye Procedure SGHT GlobeNewswire
Sep-17	Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use SGHT GlobeNewswire
Sep-09	Sight Sciences Announces the OMNI Surgical System to be Included in UnitedHealthcare's Expanded Coverage of Glaucoma Surgical Treatments SGHT GlobeNewswire
Sep-02	Sight Sciences Announces Recognition of the TearCare System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO SGHT GlobeNewswire
Aug-26	Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference SGHT GlobeNewswire
Aug-07	Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance SGHT GlobeNewswire
Jul-30	Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease SGHT GlobeNewswire
Jul-29	Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare Procedure for the Treatment of Dry Eye Disease SGHT GlobeNewswire
Jul-24	Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025 SGHT GlobeNewswire
May-14	Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th SGHT GlobeNewswire
May-08	Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance SGHT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.